99 results
Page 2 of 5
6-K
EX-99.1
zld78 chjdcxz9
6 Jul 23
Current report (foreign)
6:18am
6-K
zrzuz9 l66d
28 Jun 23
Current report (foreign)
6:02am
6-K
EX-99.1
cryor aona5yp5qn
23 Jun 23
Current report (foreign)
6:13am
6-K
00h4 edtd7idpu3x8tv
9 Jun 23
Current report (foreign)
6:03am
6-K
x5p38epuik3189 dpx
1 Jun 23
Current report (foreign)
6:02am
6-K
EX-99.1
cq65az8s6v2qc
30 May 23
Current report (foreign)
6:19am
6-K
EX-99.1
k6gp9ha2
30 May 23
Current report (foreign)
6:11am
6-K
dv1x8d4pjl5kkrj3l
17 May 23
Current report (foreign)
6:02am
6-K
bbkbes2p0waz1qmd
11 May 23
Current report (foreign)
6:10am
6-K
2a99k
11 May 23
Current report (foreign)
6:07am
6-K
7fp7od0lxir
30 Mar 23
Current report (foreign)
6:19am
6-K
yeek6mb0mc
21 Dec 22
Current report (foreign)
6:01am
6-K
EX-99.1
0hjtz2471
21 Dec 22
Current report (foreign)
6:01am
6-K
et1hl6fr
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
EX-99.1
djtsgljbh 1fic
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
gbs3u2m3le 5l
8 Dec 22
Current report (foreign)
6:46am
6-K
EX-99.1
3zjg3qbg0 9myguym
30 Nov 22
Current report (foreign)
6:28am
6-K
o6l 66et39p3t7ky5
14 Oct 22
Current report (foreign)
7:36am
6-K
8dczg mdc8w6g
4 Oct 22
Current report (foreign)
6:06am